CDKN2A and chordoma: To determine if an epigenetic mechanism could explain the p16 protein loss in some chordomas, DNA promoter methylation status of CDKN2A was assessed in four chordoma cell lines (all p16‐negative) and 35 chordoma samples, 15 of which were negative for p16 immunoreactivity.